C4 Therapeutics (CCCC) Non Operating Investment Income (2020 - 2025)
C4 Therapeutics' (CCCC) quarterly Non Operating Investment Income came in at -$73000.0 in Q2 2025, down 21.67% year-on-year from -$93191.5 in Q2 2024, and down 630.0% quarter-over-quarter from -$10000.0 in Q1 2025.
C4 Therapeutics (CCCC) Non Operating Investment Income (2020 - 2025) Analysis & Trends
C4 Therapeutics' Non Operating Investment Income history runs 6 years deep, the most recent figure standing at -$73000.0 for Q2 2025.
- On a quarterly basis, Non Operating Investment Income fell 21.67% year-over-year to -$73000.0 in Q2 2025; TTM through Jun 2025 was $410000.0, a 69.27% decrease from a year earlier, with the FY2025 full-year figure at -$3000.0, down 101.67% from the prior year.
- Non Operating Investment Income slipped to -$73000.0 in Q2 2025 per CCCC's latest filing, from -$10000.0 in the prior quarter.
- Across five years, Non Operating Investment Income topped out at $1.7 million in Q1 2023 and bottomed at -$2.9 million in Q1 2022.
- The 5-year median for Non Operating Investment Income is -$66500.0 (2024), against an average of -$2388.9.
- Biggest YoY gain for Non Operating Investment Income was 1350.0% in 2021; the steepest drop was 12500.0% in 2021.
- Year by year, Non Operating Investment Income stood at -$620000.0 in 2021, then surged by 305.16% to $1.3 million in 2022, then sank by 38.92% to $777000.0 in 2023, then plunged by 151.74% to -$402000.0 in 2024, then soared by 81.84% to -$73000.0 in 2025.
- Per Business Quant, the three latest CCCC Non Operating Investment Income figures stand at -$73000.0 (Q2 2025), -$10000.0 (Q1 2025), and -$402000.0 (Q4 2024).
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Operating Investment Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,583.17 Bn | 67,582.89 Bn | - | - |
| 2 | Nanobiotix | 1,947.22 Bn | 1,947.15 Bn | - | - |
| 3 | Akari Therapeutics | 1,132.35 Bn | 1,132.35 Bn | - | - |
| 4 | BeOne Medicines | 473.21 Bn | 468.42 Bn | 1.35 Bn | - |
| 5 | Vertex Pharmaceuticals | 123.29 Bn | 116.04 Bn | 2.59 Bn | - |
| 6 | Regeneron Pharmaceuticals | 70.05 Bn | 61.29 Bn | 3.31 Bn | - |
| 7 | Belite Bio | 63.09 Bn | 63.09 Bn | - | - |
| 8 | Argenx Se | 56.63 Bn | 51.45 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.79 Bn | 37.79 Bn | - | - |
| 10 | C4 Therapeutics | 451.98 Mn | 216.31 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2025 | -73,000.00 |
| Jun 30, 2025 | -73,000.00 |
| Mar 31, 2025 | -10,000.00 |
| Mar 31, 2025 | -10,000.00 |
| Dec 31, 2024 | -402,000.00 |
| Dec 31, 2024 | -402,000.00 |
| Sep 30, 2024 | 895,000.00 |
| Sep 30, 2024 | 895,000.00 |
| Jun 30, 2024 | -60,000.00 |
| Jun 30, 2024 | -60,000.00 |
| Mar 31, 2024 | -253,000.00 |
| Mar 31, 2024 | -253,000.00 |
| Dec 31, 2023 | 777,000.00 |
| Dec 31, 2023 | 777,000.00 |
| Sep 30, 2023 | 870,000.00 |
| Sep 30, 2023 | 870,000.00 |
| Jun 30, 2023 | 696,000.00 |
| Jun 30, 2023 | 696,000.00 |
| Mar 31, 2023 | 1.67 Mn |
| Mar 31, 2023 | 1.67 Mn |